- Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: XELOX; Drug: bevacizumab [Avastin]; Drug: mFOLFOX6; Drug: bevacizumab [Avastin]; Drug: FOLFIRI
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Actinic Keratosis
Interventions: Drug: Ingenol mebutate gel, 0.015%; Drug: Vehicle gel
Sponsors: LEO Pharma; LEO Pharma
Recruiting - verified May 2012 - Condition: Melanoma
Interventions: Drug: dabrafenib plus trametinib; Drug: dabrafenib plus trametinib placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified March 2012 - Conditions: KRAS Mutated Colorectal Adenocarcinoma.; Metastatic Pancreatic Adenocarcinoma; BRAF Mutated Melanoma
Intervention: Drug: MEK162 + AMG 479
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Duodenal Diseases
Intervention: Other: Tissue Sampling
Sponsors: South West Sydney Local Health District; South West Sydney Local Health District
Recruiting - verified March 2012 - Condition: Constriction, Pathological
Intervention: Device: Fully coated, removable , self-expanding oesophageal stent
Sponsors: South West Sydney Local Health District; South West Sydney Local Health District
Recruiting - verified March 2012 - Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsors: Bayer; Bayer
Available - verified May 2012 - Condition: Cancer
Intervention: Drug: GSK2110183
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Solid Tumors Harboring a BRAF V600 Mutation
Interventions: Drug: LGX818; Drug: MEK162
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Epithelial Ovarian Cancer
Interventions: Biological: Placebo Study Agent; Biological: Cvac
Sponsors: Prima BioMed Ltd; Prima BioMed Ltd
Recruiting - verified May 2012 - Condition: Melanoma
Interventions: Biological: Ipilimumab; Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012 - Condition: Malignant Melanoma
Intervention: Drug: DEDN6526A
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Malignant Melanoma
Intervention: Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Conditions: Metastatic Soft Tissue Sarcoma; Locally Advanced Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma
Interventions: Drug: INNO-206; Drug: Doxorubicin
Sponsors: CytRx; CytRx
Recruiting - verified March 2012 - Conditions: Head and Neck Cancer; Kidney Cancer; Liver Cancer; Sarcoma
Interventions: Drug: sorafenib tosylate; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941; Drug: carboplatin; Drug: paclitaxel; Drug: bevacizumab; Drug: Placebo
Sponsors: Genentech; Genentech
Recruiting - verified February 2012 - Condition: Metastatic Pancreatic Cancer
Interventions: Drug: MM-398; Drug: 5 Fluorouracil; Drug: Leucovorin
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma
Intervention: Drug: Eltrombopag and Vorinostat
Sponsors: Peter MacCallum Cancer Centre, Australia; Peter MacCallum Cancer Centre, Australia; GlaxoSmithKline; Merck
Not yet recruiting - verified December 2011 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Moxonidine; Drug: Placebo
Sponsors: Baker IDI Heart and Diabetes Institute; Baker IDI Heart and Diabetes Institute
Not yet recruiting - verified January 2012 - Condition: Small Cell Lung Cancer
Intervention: Drug: Lithium
Sponsors: Barwon Health; Barwon Health; Victorian Cancer Agency
Not yet recruiting - verified December 2011 - Condition: Metastatic Melanoma
Intervention: Radiation: Whole Brain Radiotherapy
Sponsors: Australia and New Zealand Melanoma Trials Group; Australia and New Zealand Melanoma Trials Group; Trans-Tasman Radiation Oncology Group (TROG); Sydney Neuro-Oncology Group
Recruiting - verified January 2012 - Condition: Smoldering Multiple Myeloma
Interventions: Drug: Siltuximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified February 2012 - Conditions: Myelodysplastic Syndromes (MDS); Acute Myeloid Leukaemia (AML)
Intervention: Drug: Azacitidine and eltrombopag
Sponsors: Peter MacCallum Cancer Centre, Australia; Peter MacCallum Cancer Centre, Australia; GlaxoSmithKline; Celgene Corporation
Recruiting - verified December 2011 - Condition: Colorectal Cancer
Interventions: Drug: Tivozanib; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; AVEO Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012 - Conditions: Acute Lymphoblastic Leukemia; Precursor B-Cell Lymphoblastic Leukemia; Precursor T-Cell Lymphoblastic Leukemia
Interventions: Drug: Decitabine; Drug: Vorinostat; Drug: Vincristine; Drug: Dexamethasone; Drug: Mitoxantrone; Drug: Pegaspargase; Drug: Methotrexate
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium
Recruiting - verified March 2012 - Condition: Multiple Myeloma
Interventions: Drug: Thalidomide; Drug: Bortezomib; Drug: Thalidomide
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC
Recruiting - verified April 2012 - Condition: Glabellar Frown Lines
Intervention: Biological: MT10109
Sponsors: Medy-Tox; Medy-Tox
Recruiting - verified April 2012 - Condition: Carcinoma, Renal Cell
Intervention: Drug: Pazopanib followed by everolimus
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Renal Cell Carcinoma
Intervention: Drug: Axitinib
Sponsors: Pfizer; Pfizer
Available - verified May 2012 - Condition: Lung Neoplasms
Interventions: Drug: Afatinib; Drug: gefitinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Actinic Keratoses
Interventions: Drug: Metvix and natural daylight PDT; Drug: Metvix and conventional PDT
Sponsors: Galderma; Galderma
Recruiting - verified May 2012 - Condition: Neoplasms
Interventions: Drug: RO5503781; Drug: RO5503781
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab [MetMAb]; Drug: erlotinib [Tarceva]; Drug: Placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified January 2012 - Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified October 2011 - Condition: Leukemia, Pediatric
Intervention: Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Children's Oncology Group; EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Eribulin; Drug: TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012 - Condition: Gastric Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: capecitabine; Drug: cisplatin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Myelodysplastic Syndrome
Interventions: Drug: Siltuximab + BSC; Drug: Placebo + BSC
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012 - Condition: Advanced Solid Tumors
Interventions: Drug: ABT-806; Drug: ABT-806i
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Advanced and Selected Solid Tumors
Intervention: Drug: BYL719 plus MEK162
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Hematopoietic Neoplasm
Interventions: Drug: SAR302503; Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: anti-cancer therapy
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Peripheral T-cell Lymphoma
Interventions: Drug: Pralatrexate Injection; Dietary Supplement: Vitamin B12; Dietary Supplement: Folic Acid
Sponsors: Allos Therapeutics; Allos Therapeutics
Recruiting - verified March 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: Toowoomba Regional Cancer Research Centre; Toowoomba Regional Cancer Research Centre; Abbott
Recruiting - verified June 2011 - Condition: Juvenile Idiopahtic Arthritis
Intervention: Drug: etanercept
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Human Papillomavirus
Intervention:
Sponsors: The Alfred; The Alfred; Merck
Recruiting - verified August 2011 - Condition: Glioblastoma
Interventions: Drug: BKM120 + temozolomide; Drug: BKM120 +temozolomide with/without radiotherapy
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Cognitive/Functional Effects; Leukemia; Neurotoxicity; Pain; Therapy-related Toxicity
Interventions: Drug: clofarabine; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: hydrocortisone sodium succinate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Oral Mucositis
Interventions: Biological: ALD518; Drug: 0.9% saline
Sponsors: Alder Biopharmaceuticals, Inc.; Alder Biopharmaceuticals, Inc.
Recruiting - verified April 2012 - Condition: Von Willebrand Disease
Intervention: Biological: Recombinant von Willebrand factor (rVWF) with or without rFVIII (Advate)
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation; Baxter Innovations GmbH
Recruiting - verified March 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: MEGF0444A; Drug: mFOLFOX6; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Advanced Solid Tumors
Intervention: Drug: ABT-806
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Condition: Melanoma
Interventions: Drug: Ipilimumab (BMS-734016); Biological: Vemurafenib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Roche-Genentech
Recruiting - verified November 2011 - Condition: Lymphoma
Intervention: Drug: SAR245409
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Pancreatic Cancer
Intervention: Drug: dasatinib
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified February 2012 - Condition: Glioma
Interventions: Drug: temozolomide (TMZ); Drug: bevacizumab [Avastin]; Radiation: Radiotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012 - Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012 - Condition: Malignant Melanoma
Intervention: Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Islet Cell Tumor
Interventions: Drug: Everolimus; Drug: Pasireotide + Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Prostate Cancer (Post Prostatectomy); Anal Cancer; Nasopharyngeal Cancer; Intermediate Risk Prostate Cancer
Intervention: Other: Non-Interventional Study
Sponsors: Trans-Tasman Radiation Oncology Group (TROG); Trans-Tasman Radiation Oncology Group (TROG)
Recruiting - verified June 2011 - Condition: Leukemia
Interventions: Drug: asparaginase; Drug: bortezomib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: mitoxantrone hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012 - Conditions: Colonic Polyp; Colon Cancer
Intervention: Other: Sample of polyp
Sponsors: South West Sydney Local Health District; South West Sydney Local Health District
Recruiting - verified March 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab; Drug: carboplatin; Drug: MEGF0444A; Drug: paclitaxel; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Colonic Polyps
Interventions: Procedure: Circumferential Submucosal Incision Resection; Procedure: Endoscopic Muscosal Resection
Sponsors: South West Sydney Local Health District; South West Sydney Local Health District
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified February 2012 - Condition: Adenomatous Polyp of Large Intestine
Intervention: Procedure: Prophylactic use of coagulation therapy
Sponsors: South West Sydney Local Health District; South West Sydney Local Health District
Recruiting - verified March 2012 - Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: BMS-833923
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified November 2011 - Condition: Breast Cancer
Interventions: Drug: azacitidine; Drug: entinostat; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Colon Cancer and Rectal Cancer
Intervention: Drug: E7820
Sponsors: Eisai Inc.; Eisai Inc.; PharmaBio Development Inc.
Recruiting - verified April 2012 - Condition: Head and Neck Neoplasms
Interventions: Drug: Placebo; Drug: Afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Brain and Central Nervous System Tumors; Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Procedure: acupressure therapy; Procedure: sham intervention
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011 - Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified April 2012 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: RO5072759; Drug: rituximab [MabThera/Rituxan]; Drug: chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Melanoma
Intervention: Drug: LGX818
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Interventions: Drug: RO5083945; Drug: FOLFIRI; Drug: cetuximab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Conditions: Unspecified Adult Solid Tumor, Protocol Specific; Solid Tumor
Intervention: Drug: BEZ235 + MEK162
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Breast Neoplasms
Interventions: Drug: Vinorelbine Weekly; Drug: Afatinib once daily (OD)
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Chronic Lymphocytic Leukemia; Non-Hodgkin's Lymphoma
Intervention: Drug: ABT-199
Sponsors: Abbott; Abbott; Genentech
Recruiting - verified March 2012 - Condition: Multiple Myeloma
Intervention: Drug: pomalidomide
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012 - Condition: Basal Cell Carcinoma
Intervention: Drug: LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Soft Tissue Sarcoma
Interventions: Drug: Eribulin mesylate 1.4 mg/m2 intravenous; Drug: Dacarbazine of 850 mg/m2, or 1,000 mg/m2, or 1,200 mg/m2 IV
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified May 2012 - Condition: Thyroid Cancer
Interventions: Drug: lenvatinib 24 mg administered orally, once a day; Drug: Placebo 24mg administered orally, once a day
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: pomalidomide; Drug: dexamethasone
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Docetaxel (XRP6976); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Conventional Chondrosarcoma
Interventions: Drug: IPI-926; Drug: Placebo Arm
Sponsors: Infinity Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Conditions: Fungal Infection; Leukemia; Neutropenia
Interventions: Drug: caspofungin acetate; Drug: fluconazole
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Malignant Melanoma
Intervention: Drug: RO5185426
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Cervical Intraepithelial Neoplasia
Interventions: Biological: VGX 3100; Biological: Placebo
Sponsors: Inovio Pharmaceuticals; Inovio Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Locally Advanced or Metastatic Medullary Thyroid Cancer; Medullary Thyroid Cancer
Intervention: Behavioral: Patient outreach
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified November 2011 - Condition: Cancer, Solid Tumor
Interventions: Drug: MK-3475 1 mg/kg; Drug: MK-3475 3 mg/kg; Drug: MK-3475 10 mg/kg; Drug: MK-3475 MEL; Drug: MK-3475 NSCLC
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: Irintoecan; Drug: HA-Irinotecan solution for Infusion
Sponsors: Alchemia Oncology; Alchemia Oncology
Recruiting - verified January 2012 - Condition: Lymphoma, B-Cell
Interventions: Drug: RO5072759; Drug: rituximab [MabThera/Rituxan]; Drug: CHOP chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: rituximab [MabThera]; Drug: rituximab [MabThera]; Drug: rituximab [MabThera]; Drug: Fludarabine; Drug: Cyclophosphamide
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Lung Cancer - Non Small Cell
Interventions: Drug: Ipilimumab; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Advanced Endometrial Cancer
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Tumors Characterized by Genetic Abnormalities of ALK
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Cancer
Intervention: Drug: BMS-906024
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Condition: Breast Cancer
Interventions: Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: International Breast Cancer Study Group; International Breast Cancer Study Group
Recruiting - verified March 2012 - Condition: Indolent B-cell NHL
Intervention: Drug: Bendamustine IV
Sponsors: Mundipharma Research Limited; Mundipharma Research Limited
Recruiting - verified February 2012 - Condition: Follicular Lymphoma
Intervention: Drug: HCD122
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: GDC-0973
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified February 2012 - Condition: Prostate Cancer Metastatic
Intervention: Drug: CABAZITAXEL
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Non Hematologic, Malignant Solid Tumour, Excluding Primary Brain or Spinal Tumours
Intervention: Drug: PG545
Sponsors: Progen Pharmaceuticals; Progen Pharmaceuticals; Statistical Revelations Pty Ltd; Datapharm Australia Pty Ltd
Recruiting - verified June 2011 - Condition: Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.
Intervention: Biological: GSK580299 (CervarixTM)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012 - Condition: Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified May 2012 - Condition: Polycythemia Vera
Interventions: Drug: INC424 tablets; Other: Best Available Therapy (BAT)
Sponsors: Incyte Corporation; Incyte Corporation; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention: Drug: tasquinimod
Sponsors: Active Biotech AB; Active Biotech AB
Recruiting - verified April 2012 - Condition: Cancer
Intervention: Drug: BMS-911543
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified November 2011 - Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Sarcoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: topotecan hydrochloride; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Carcinoma; Hepatocellular
Intervention: Drug: LY2157299
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Cancer
Interventions: Drug: GSK2118436; Drug: GSK1120212; Drug: Other approved anti-cancer agent
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: Adenocarcinoma of the Pancreas; Advanced Solid Tumors; Cancer; Cancer of Pancreas; Cancer of the Pancreas; Metastases; Metastatic Cancer; Metastatic Pancreatic Cancer; Pancreas Cancer; Pancreatic Cancer; Bone Metastases; Endocrine Cancer; Oncology; Oncology Patients; Solid Tumors; Advanced Malignancy
Interventions: Drug: AMG 479; Drug: Placebo; Drug: AMG 479; Drug: gemcitabine
Sponsors: Amgen; Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Condition: Sarcoma
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: temsirolimus; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012 - Condition: Adenocarcinoma of the Lung
Interventions: Biological: farletuzumab; Other: Placebo; Drug: Platinum Containing Doublet
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified April 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: irinotecan hydrochloride; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Colorectal Neoplasms
Intervention: Drug: 111In-CS-1008, CS-1008
Sponsors: Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; Daiichi Sankyo Inc.
Recruiting - verified June 2011 - Condition: Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsors: Medivation, Inc.; Medivation, Inc.; Astellas Pharma Inc
Recruiting - verified February 2012 - Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Dovitinib; Drug: Sorafenib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Melanoma; NY-ESO-1-positive; Progressive Metastatic Cutaneous Melanoma; Unresectable
Intervention: Biological: GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: Acute Myeloid Leukemia (AML); Acute Lymphocytic Leukemia (ALL); Chronic Myelogenous Leukemia (CML); Myelodysplastic Syndrome (MDS); Myeloproliferative Neoplasms (MPN)
Intervention: Drug: KB004, Monoclonal Antibody
Sponsors: KaloBios Pharmaceuticals; KaloBios Pharmaceuticals
Recruiting - verified October 2011 - Condition: Advanced Cancer
Intervention: Drug: LY2874455
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: LY2127399; Drug: Placebo every 4 weeks; Drug: Placebo every 2 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012 - Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Mabthera intravenous; Drug: MabThera subcutaneous
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: AMG 386 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Leukemia; Acute Myeloid Leukemia; Acute Nonlymphocytic Leukemia
Interventions: Drug: vosaroxin and cytarabine; Drug: placebo and cytarabine
Sponsors: Sunesis Pharmaceuticals; Sunesis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Non Small Cell Lung Cancer
Intervention: Drug: OMP-21M18
Sponsors: OncoMed Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; Novotech (Australia) Pty Ltd
Recruiting - verified October 2010 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Pancreatic Cancer
Intervention: Drug: OMP-21M18
Sponsors: OncoMed Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; Novotech (Australia) Pty Ltd
Recruiting - verified December 2010 - Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Interventions: Biological: Ramucirumab; Drug: Irinotecan; Biological: Placebo; Drug: Folinic Acid; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified April 2012 - Condition: Non-Hodgkin's Lymphoma (NHL)
Interventions: Drug: temsirolimus; Drug: temsirolimus
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Pediatric Acute Myelogenous Leukemia (AML)
Interventions: Drug: Decitabine; Drug: Decitabine
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012 - Condition: Gastric Cancer
Interventions: Biological: Ramucirumab DP; Drug: Placebo; Drug: Paclitaxel
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified December 2011 - Condition: Soft Tissue Sarcoma
Interventions: Drug: doxorubicin in combination with palifosfamide-tris; Drug: doxorubicin in combination with placebo
Sponsors: ZIOPHARM; ZIOPHARM
Recruiting - verified April 2012 - Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide; Other: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Colorectal Cancer, Malignant Melanoma, Neoplasms
Intervention: Drug: RO5212054
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Other: cytology specimen collection procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Symptomatic Waldenstroms Macroglobulinaemia
Intervention: Drug: Belimumab
Sponsors: Cancer Trials Australia; Cancer Trials Australia; Human Genome Sciences
Recruiting - verified February 2012 - Condition: Cancer
Intervention: Drug: GSK2256098
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified December 2011 - Condition: Hepatocellular Carcinoma
Interventions: Biological: Placebo; Biological: Ramucirumab DP (IMC-1121B)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2012 - Condition: Unresectable Stage III or Stage IV Melanoma
Interventions: Drug: E7080; Drug: E7080
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified January 2012 - Conditions: Colorectal Cancer; Colorectal Carcinoma; Colorectal Tumors; Neoplasms, Colorectal
Interventions: Drug: Panitumumab; Drug: Irinotecan; Drug: Everolimus
Sponsors: The Queen Elizabeth Hospital; The Queen Elizabeth Hospital; Amgen; Novartis
Recruiting - verified July 2011 - Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: trastuzumab; Drug: vinorelbine; Drug: vinorelbine
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Medulloblastoma,; Rhabdomyosarcoma,; Neuroblastoma,; Hepatoblastoma,; High Grade Glioma,; Astrocytoma
Intervention: Drug: LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: COMBINED PF-02341066 AND PF-00299804; Drug: PF-00299804 FOLLOWED BY COMBINED PF-02341066 AND PF-00299804
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: PEG-L-asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: mercaptopurine; Drug: methotrexate; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Drug: vindesine; Drug: daunoxome; Drug: fludarabine; Radiation: Radiation Therapy
Sponsors: University of Schleswig-Holstein; University of Schleswig-Holstein; Deutsche Krebshilfe e.V., Bonn (Germany); medac GmbH (for drug supply in randomization R2 and R-HR)
Recruiting - verified November 2011 - Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: pertuzumab; Drug: pertuzumab-placebo; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech
Recruiting - verified March 2012 - Condition: Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4
Intervention: Drug: Cilengitide
Sponsors: Northern Sydney and Central Coast Area Health Service; Northern Sydney and Central Coast Area Health Service; Merck KGaA
Recruiting - verified July 2011 - Condition: Liver Transplant Recipient
Interventions: Drug: Tacrolimus; Drug: Tacrolimus + everolimus; Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Acute Myeloid Leukemia (AML)
Interventions: Drug: Elacytarabine; Drug: Investigator's Choice
Sponsors: Clavis Pharma; Clavis Pharma
Recruiting - verified April 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Lymphoma; Diffuse Large B-cell Lymphoma
Interventions: Drug: Lenalidomide; Drug: Placebo
Sponsors: Groupe d'Etude des Lymphomes de l'Adulte - Recherche Clinique; Groupe d'Etude des Lymphomes de l'Adulte - Recherche Clinique
Recruiting - verified June 2011 - Condition: Endometrial Cancer
Intervention:
Sponsors: Queensland Centre for Gynaecological Cancer; Queensland Centre for Gynaecological Cancer; Greenslopes Private Hospital; The University of Queensland; Sullivan and Nicolaides Pathology
Recruiting - verified June 2011 - Conditions: Non-Hodgkin's Lymphoma; Mantle Cell Lymphoma
Intervention: Drug: bendamustine and rituximab
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified April 2012 - Conditions: Nausea; Vomiting; Genital Neoplasms, Female
Interventions: Drug: Fosaprepitant dimeglumine; Drug: Placebo
Sponsors: Odense University Hospital; Odense University Hospital; Helsinn Healthcare SA
Recruiting - verified January 2012 - Condition: Acute Myeloid Leukemia
Interventions: Drug: A: Azacitidine (Vidaza); Drug: B: Conventional Care Regimen
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012 - Condition: Fungal Infection
Interventions: Drug: posaconazole; Drug: Dextrose 5% in water (1) posaconazole (2); Drug: posaconazole; Drug: posaconazole; Drug: posaconazole; Drug: Posaconazole
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012 - Condition: Cancer
Interventions: Drug: GSK2118436; Drug: GSK1120212
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified December 2011 - Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012 - Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Carcinoma
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Biological: Ofatumumab; Other: No Intervention
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Anemia
Interventions: Drug: Lenalidomide; Other: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012 - Condition: Melanoma
Intervention: Drug: nilotinib (AMN107)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple MyelomaCondition: Multiple Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Castleman's Disease
Interventions: Drug: Placebo; Drug: CNTO 328
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012 - Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab; Drug: Placebo + vinorelbine + trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Stage IV Resectable Melanoma
Interventions: Procedure: Surgery; Procedure: Surgery plus 2 adjuvant doses of BCG; Other: best medical therapy
Sponsors: John Wayne Cancer Institute; John Wayne Cancer Institute; Melanoma Research Alliance
Recruiting - verified May 2012 - Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: RO5072759; Drug: rituximab; Drug: chlorambucil
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech; German CLL Study Group
Recruiting - verified April 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: Cetuximab (Erbitux); Drug: Panitumumab (Vectibix)
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Breast Reconstruction; Mastectomy
Intervention: Device: Patient Activated Controlled Expansion Device
Sponsors: AirXpanders, Inc.; AirXpanders, Inc.
Recruiting - verified April 2012 - Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Solid Tumors; Cancer
Interventions: Drug: MSC1936369B; Drug: MSC1936369B; Drug: MSC1936369B; Drug: MSC1936369B
Sponsors: Merck KGaA; Merck KGaA; Merck Serono S.A., Geneva
Recruiting - verified August 2011 - Conditions: Relapsed T-Cell Acute Lymphoblastic Leukemia; Relapsed T-Cell Lymphoblastic Lymphoma
Interventions: Drug: Nelarabine; Drug: Etoposide; Drug: Cyclophosphamide; Drug: Methotrexate; Drug: Filgrastim
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; GlaxoSmithKline
Recruiting - verified November 2011 - Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Conditions: Pancreatic Neoplasm; Pituitary Neoplasm; Nelson Syndrome; Ectopic ACTH Syndrome
Intervention: Drug: Pasireotide LAR
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011 - Condition: Myelodysplastic Syndromes
Interventions: Drug: Deferasirox; Drug: Deferasirox placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: gemcitabine; Drug: gemcitabine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Human Papillomavirus (HPV) Type 16/18 Infections; Cervical Neoplasia
Intervention: Procedure: Gynaecological follow-up
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012 - Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified March 2012 - Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Small Cell Lung Carcinoma
Interventions: Drug: BMS-833923; Drug: Carboplatin; Drug: Etoposide
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified February 2012 - Condition: B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Interventions: Drug: Lenalidomide; Drug: Chlorambucil
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified September 2011 - Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified January 2012 - Condition: Neuroblastoma
Interventions: Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: nucleic acid amplification; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: cytology specimen collection procedure; Other: flow cytometry; Procedure: biopsy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Hepatocellular Carcinoma
Interventions: Drug: Brivanib; Drug: Brivanib Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Bone Metastases
Intervention: Device: Bone Scan: F18-Fluoride PET/CT or TC-MDP
Sponsors: American College of Radiology - Image Metrix; American College of Radiology - Image Metrix; Academy of Molecular Imaging
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: Standard taxane therapy; Drug: capecitabine [Xeloda]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Conditions: Breast Neoplasms; Heart Failure
Intervention:
Sponsors: Royal Prince Alfred Hospital, Sydney, Australia; Royal Prince Alfred Hospital, Sydney, Australia
Recruiting - verified July 2011 - Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; Kirby Institute; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified April 2012 - Conditions: Advanced Malignancy; Advanced Solid Tumors; Cancer; Solid Tumors; Tumors
Interventions: Drug: Arm 1- Dose Escalation; Drug: Arm 1- Dose Expansion
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Intervention: Other: Enteral feeding
Sponsors: Queensland Centre for Gynaecological Cancer; Queensland Centre for Gynaecological Cancer; Cancer Australia; The University of Queensland
Recruiting - verified June 2011 - Condition: Neurofibromatosis Type 1
Interventions: Drug: Lovastatin ™; Device: placebo
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Children's Hospital Boston; Children's Hospital Philadelphia; Children's Research Institute; Children's Hospital Medical Center, Cincinnati; National Cancer Institute (NCI); University of Chicago; University of Utah; Washington University School of Medicine; The Children's Hospital at Westmead
Recruiting - verified July 2011 - Condition: Prostate Cancer
Intervention:
Sponsors: Barwon Health; Barwon Health
Recruiting - verified August 2011 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: RO5072759; Drug: RO5072759; Drug: CHOP(cyclophosphamide,doxorubicin,vincristine,prednisone); Drug: FC(fludarabine,cyclophosphamide); Drug: RO5072759; Drug: bendamustine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: BMS-754807; Drug: trastuzumab (Herceptin®)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified November 2010 - Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Leukemia
Intervention: Drug: Midostaurin
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: B-cell Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - Condition: Solid Tumors
Intervention: Drug: AZD2281
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2012 - Conditions: Cancer; Carcinoma; Fallopian Tube Cancer; Gynecological Malignancies; Metastases; Oncology; Ovarian Cancer; Solid Tumors; Tumors
Interventions: Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin; Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin; Drug: B1: AMG 386 10 mg/kg + Topotecan; Drug: B3: AMG 386 15mg/kg + Topotecan
Sponsors: Amgen; Amgen
Recruiting - verified September 2011 - Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: CHRONIC MYELOGENOUS LEUKEMIA
Interventions: Drug: Nilotinib; Drug: Imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Soft Tissue Sarcoma
Interventions: Drug: Sunitinib malate; Radiation: Radiotherapy
Sponsors: Australasian Sarcoma Study Group; Australasian Sarcoma Study Group; Peter MacCallum Cancer Centre, Australia; Pfizer
Recruiting - verified December 2010 - Conditions: Pain; Cancer
Interventions: Biological: Tetrodotoxin; Biological: Placebo
Sponsors: Wex Pharmaceuticals Inc.; Wex Pharmaceuticals Inc.
Recruiting - verified May 2011 - Conditions: Colorectal Cancer; Colorectal Carcinoma; Liver Metastases
Interventions: Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres; Drug: Systemic chemotherapy (FOLFOX)
Sponsors: Sirtex Medical; Sirtex Medical
Recruiting - verified May 2012 - Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Conditions: Cancer; GCT; Giant Cell Tumor of Bone; Benign GCT
Intervention: Drug: Denosumab
Sponsors: Amgen; Amgen
Recruiting - verified January 2012 - Conditions: Haemoglobinopathies,; Myelodysplastic Syndromes,; Other Inherited or Acquired Anaemia (e.g. MPD, Diamond-blackfan Anaemia and Other Rare Anaemias),; Transfusional Iron Overload
Intervention: Drug: deferasirox
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: etoposide phosphate; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate; Genetic: mutation analysis; Other: immunohistochemistry staining method; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Venous Thrombosis
Interventions: Drug: Enoxaparin; Drug: warfarin; Drug: Placebo for apixaban; Drug: Placebo for enoxaparin; Drug: Placebo for warfarin; Drug: apixaban
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer
Recruiting - verified October 2010 - Conditions: Melanoma; Breast Cancer; Prostate Cancer
Intervention: Drug: CVA21
Sponsors: Viralytics; Viralytics
Recruiting - verified October 2011 - Condition: Advanced Malignancies
Intervention: Drug: NPI 0052
Sponsors: Nereus Pharmaceuticals, Inc.; Nereus Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Conditions: Aspergillosis; Invasive Fungal Infections
Intervention: Drug: isavuconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Genetic: DNA methylation analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group; Radiation Therapy Oncology Group; Medical Research Council; Cooperative Trials Group for Neuro-Oncology
Recruiting - verified May 2011 - Condition: Head and Neck Cancer
Interventions: Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2011 - Condition: Neoplasms
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; Bayer; ICON Clinical Research
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention: Biological: Gene Directed Enzyme Prodrug Therapy, FP253/Fludarabine
Sponsors: Biotech Equity Partners Pty Ltd; Biotech Equity Partners Pty Ltd
Recruiting - verified July 2011 - Condition: Cervical Cancer
Interventions: Procedure: Total Abdominal Radical Hysterectomy; Procedure: Total Laparoscopic or Robotic Radical Hysterectomy
Sponsors: Queensland Centre for Gynaecological Cancer; Queensland Centre for Gynaecological Cancer; M.D. Anderson Cancer Center
Recruiting - verified June 2011 - Conditions: Systemic Anaplastic Large-Cell Lymphoma; Neoplasms; Anaplastic Lymphoma Kinase, Human; NSCLC
Interventions: Drug: PF-02341066; Drug: Rifampin; Drug: Ketoconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Letrozole; Drug: Letrozole
Sponsors: International Breast Cancer Study Group; International Breast Cancer Study Group
Recruiting - verified March 2012 - Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy; Procedure: videothoracoscopy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified April 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: paclitaxel; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified April 2012 - Conditions: Ototoxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Procedure: management of therapy complications
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Myelodysplastic Syndromes; Secondary Myelofibrosis
Interventions: Biological: filgrastim; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); The Canadian Blood and Marrow Transplant Group; National Cancer Institute (NCI)
Recruiting - verified July 2009 - Conditions: Metastatic Breast Cancer; Advanced Breast Cancer; Gastrointestinal Stromal Tumor; Hepatocellular Carcinoma; Metastasizing Breast Cancer (F); Metastatic Castration-Resistant Prostrate Cancer; Metastatic Renal Cell Cancer; Non Small Cell Lung Cancer; Pancreatic Islet Cell Carcinoma
Intervention: Drug: sunitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: depsipeptide; Drug: bortezomib; Drug: dexamethasone
Sponsors: Peter MacCallum Cancer Centre, Australia; Peter MacCallum Cancer Centre, Australia; Celgene Corporation; Janssen-Cilag Ltd.
Recruiting - verified August 2011 - Conditions: Mycoses; Candidiasis, Invasive; Candidemia
Interventions: Drug: Isavuconazole; Drug: Caspofungin; Drug: Voriconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2012 - Conditions: Invasive Fungal Infection; Aspergillosis
Interventions: Drug: Isavuconazole; Drug: Voriconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2012 - Conditions: Leukemia; Lymphoma
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Unruptured Brain Arteriovenous Malformation
Intervention: Procedure: invasive therapy [endovascular procedures, neurosurgery, or radiotherapy, alone or in combination]
Sponsors: Columbia University; Columbia University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified September 2011 - Conditions: Kidney Cancer; Metastatic Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Kidney Neoplasms
Interventions: Drug: Sunitinib malate; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Breast Cancer; Neoplasm Metastasis
Interventions: Other: Standard supportive care (packed RBC transfusion); Drug: epoetin alfa + packed RBC transfusion
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified July 2011 - Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Melanoma
Interventions: Procedure: Completion Lymphadenectomy; Procedure: Monitoring with nodal ultrasound
Sponsors: John Wayne Cancer Institute; John Wayne Cancer Institute; National Institutes of Health (NIH)
Recruiting - verified January 2012 - Conditions: Hypereosinophilic Syndrome; Systemic Mastocytosis; Chronic Myelomonocytic Leukemia; Dermatofibrosarcoma
Intervention: Drug: imatinib mesylate
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With OsteosarcomaCondition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified June 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: cisplatin; Drug: cyclophosphamide; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Radiation: radiation therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified January 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cisplatin; Drug: cytarabine; Drug: dexamethasone; Drug: gemcitabine hydrochloride; Other: clinical observation
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012 - Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: CAF regimen; Drug: CMF regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: methotrexate; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); International Breast Cancer Study Group
Recruiting - verified September 2008 - Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer - EORTC; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified December 2011
 |
Cancer Clinical Trials - Join clinical trials for Cancer in Australia |
